Test Price
2,800 AED✅ Home Collection Available
ARSE Gene Sequencing Test for X-Linked Recessive Chondrodysplasia Punctata in the UAE
Executive Summary & Core Metrics
Executive Summary: DNA Labs UAE offers the most advanced ARSE gene sequencing service in the UAE, delivering a definitive molecular diagnosis for X-linked recessive chondrodysplasia punctata (CDPX1). This diagnostic asset leverages Next-Generation Sequencing (NGS) to achieve 99.9% clinical sensitivity, supported by ISO 9001:2015 accredited processing. Patients benefit from VIP mobile phlebotomy with a temperature-controlled cold chain (available daily 8 AM to 11 PM) and a mandatory post-test telephonic interpretation session conducted by a DHA-licensed Consultant Medical Geneticist.
Test Overview & Methodology
This single-gene test sequences the entire coding region and critical intronic boundaries of the ARSE gene. X‑linked recessive chondrodysplasia punctata (CDPX1) is a rare skeletal dysplasia. A precise molecular diagnosis is essential to differentiate it from other peroxisomal or vitamin K‑dependent disorders, enabling accurate prognosis, targeted monitoring, and informed family planning.
Our methodology employs Illumina® NGS chemistry with orthogonal Sanger confirmation for all clinically actionable variants, ensuring the highest standard of diagnostic fidelity available in the Gulf region.
| Feature | DNA Labs UAE ARSE Assay | Conventional Alternative |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity; full gene coverage including deep intronic splice sites | Sanger sequencing of selected exons only (misses mosaic or deep intronic variants) |
| Analysis Platform | Next‑Generation Sequencing (NGS) with orthogonal confirmation | Conventional PCR + Sanger; lower throughput, higher rate of inconclusive results |
| Turnaround Time | 21 – 28 Business Days | 6 – 8 Weeks (often outsourced abroad) |
| Regulatory Compliance | DHA‑registered facility; ISO 9001:2015; full PDPL compliance | May lack local DHA accreditation or structured data privacy framework |
Physician Insight & Safety Protocols
“A definitive molecular diagnosis is the cornerstone of informed family planning and clinical management. In X‑linked recessive chondrodysplasia punctata, confirming a pathogenic ARSE variant enables targeted monitoring for respiratory, skeletal, and dermatological manifestations, ensuring timely intervention across the patient’s lifespan. I always correlate the genetic data with the complete clinical and radiological picture.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication & Treatment Advisory
Important Advisory: This genetic test provides diagnostic information and does not replace an ongoing treatment plan. Patients should continue all prescribed therapies unless explicitly directed otherwise by their managing physician. Do not alter or discontinue medications based solely on genetic findings without consulting a specialist.
Exclusion Criteria & Contraindications
- Unwillingness or inability to provide valid written informed consent (for minors, legal guardian consent is mandatory per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Inadequate or compromised DNA sample (e.g., clotted blood, insufficient volume, or degraded buccal specimen).
- Active febrile illness, hematological malignancy, or bleeding disorder — defer collection until clinically stable.
- Emergency Red Flags: If the patient exhibits severe respiratory distress, seizures, or acute skeletal pain crises, seek immediate medical attention; genetic testing must not delay emergency care.
- Pregnancy does not contraindicate this blood/buccal test, but prenatal diagnosis requires separate amniocentesis or CVS under specialist guidance.
Patient FAQ & Clinical Guidance
1. What is the clinical accuracy of this genetic test?
Snippet: With Next‑Generation Sequencing and ISO 9001:2015 accreditation, this assay delivers 99.9% diagnostic sensitivity for clinically significant ARSE gene mutations.
The test covers all coding exons, canonical splice sites, and critical deep intronic regions. Positive findings are confirmed via an independent sequencing method, while negative results are reported with a 99.9% confidence that no pathogenic variant exists in the analyzed regions. This rigor ensures that families receive definitive answers for managing CDPX1.
2. How are my results delivered and interpreted?
Snippet: Results are delivered via a secure digital portal and include a complimentary post-test telephonic guidance session with a DHA-licensed Consultant Medical Geneticist.
You will receive a comprehensive PDF report classifying the identified variant as pathogenic, likely pathogenic, or a variant of uncertain significance (VUS). A bilingual genetic counselor is available to explain the implications for your family in your preferred language.
3. Is home blood collection safe and culturally appropriate in the UAE?
Snippet: Our DHA‑licensed mobile phlebotomists adhere to strict hygiene and privacy protocols, ensuring full respect for UAE cultural and religious standards.
The collection procedure uses a sterile, single-use vacutainer system. Female patients can request a female phlebotomist, and all visits are conducted in the privacy of your home within a scheduled time window that suits your family (8 AM to 11 PM).
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the stringent oversight of the Dubai Health Authority (DHA) and adheres to the highest standards of patient confidentiality and data security.
- Data Privacy Framework: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Healthcare ICT Compliance: Adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability & Safety: All clinical safety protocols conform to Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Accreditations: Our laboratory holds ISO 9001:2015 certification, ensuring consistent quality management and diagnostic integrity.
Clinical & Logistical Metadata
| Test Name | ARSE Gene Sequencing (X‑Linked Recessive Chondrodysplasia Punctata) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21 – 28 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood or Buccal Swab (VIP Mobile Phlebotomy Available Daily 8 AM – 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) with Orthogonal Sanger Confirmation |
| ICD-10-CM Code | Q77.3 |
| LOINC Code | 94231-7 |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians